Sunday 18 October 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.
6.04
0.64
−9.58%
Follow AGEN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 2 | 4 | 2 | 7 | 2 | 3 | 2 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(8.73) | (11.52) | (14.25) | (11.54) | (10.29) | (2.17) | (6.06) | (10.06) | (15.67) | (14.16) |
P/S ratio |
15.75 | 7.97 | 7.03 | 3.59 | 6.11 | 2.45 | 6.77 | 1.83 | 0.57 | 0.82 |
Altman Z″-Score (non-manufacturers) |
(21.50) | (28.78) | (34.50) | (32.14) | (26.96) | (7.47) | (16.13) | (27.06) | (40.73) | (38.05) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.89) | (3.44) | (3.59) | 0.44 | (4.63) | (1.17) | 0.09 | 1.93 | (5.29) | 12.57 |
P/Operating CF |
(22.06) | (13.22) | (7.22) | (16.96) | (15.12) | (31.55) | (14.02) | (7.09) | (2.05) | (5.62) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.73 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
18.15 | 10.37 | 5.95 | 3.27 | 5.20 | 1.45 | 4.93 | 1.43 | 0.50 | 1.39 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.22 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(5.12) | (4.72) | (1.67) | (26.30) | (3.29) | 42.39 | (2.76) | (1.00) | (0.33) | (2.05) |
EV/FCF |
(4.43) | (4.57) | (1.63) | (21.05) | (3.21) | (23.87) | (2.34) | (0.97) | (0.32) | (2.06) |
Quick Ratio |
2.15 | 1.09 | 0.79 | 0.64 | 0.78 | 1.97 | 1.04 | 0.40 | 0.18 | 0.03 |
Current Ratio |
2.24 | 1.30 | 1.10 | 0.71 | 0.88 | 2.12 | 1.13 | 0.44 | 0.21 | 0.41 |
Net Debt/EBITDA |
(0.53) | (1.05) | 0.34 | 0.75 | 0.73 | (9.02) | 1.04 | 0.43 | 0.07 | (4.10) |
Debt/Assets |
83.25% | 117.79% | 9.79% | 9.03% | 9.19% | 2.91% | 3.18% | 4.11% | 14.66% | 19.69% |
Debt/Equity |
(3.34) | (2.15) | (0.08) | (0.06) | (0.09) | 0.28 | (0.24) | (0.09) | (0.11) | (0.16) |
Asset Turnover |
0.11 | 0.29 | 0.27 | 1.03 | 0.48 | 0.87 | 0.22 | 0.43 | 0.38 | 0.50 |
Operating CF/Net income |
0.63 | 0.78 | 0.82 | 0.17 | 0.77 | (0.42) | 0.80 | 0.91 | 0.70 | 764.31 |
Capex/Depreciation |
(2.53) | (0.50) | (0.57) | (0.70) | (0.48) | (4.15) | (4.47) | (0.49) | (0.04) | 0.04 |
Interest Coverage |
(6.21) | (5.50) | (4.90) | (1.69) | (1.92) | 0.39 | (2.90) | (1.63) | (1.02) | (0.36) |
| (805.04%) | 210.36% | 127.73% | 53.15% | 81.80% | 29.51% | 6,300.19% | 242.00% | 100.01% | 0.03% | |
| (63.72%) | (81.86%) | (116.37%) | (73.95%) | (97.94%) | (7.09%) | (50.09%) | (67.62%) | (84.20%) | (0.04%) | |
ROIC |
(444.11%) | (240.08%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(167.16%) | (279.25%) | (501.85%) | 1,154.01% | (1,694.48%) | (10.27%) | (140.14%) | 2,445.07% | 408.01% | 0.06% |
Average Days of Receivables |
183.56 | 9.66 | 9.31 | 39.63 | 4.79 | 1.87 | 10.21 | 60.33 | 1.44 | 22.41 |
Research and Development Expense of Revenue |
420.72% | 270.83% | 338.73% | 112.19% | 161.75% | 60.41% | 190.45% | 150.06% | 150.32% | 69.48% |
Selling, General and Administrative Expense of Revenue |
146.75% | 78.69% | 101.51% | 30.68% | 67.16% | 25.83% | 82.64% | 50.37% | 69.47% | 47.63% |
Intangible Assets out of Total Assets |
0.25 | 0.27 | 0.26 | 0.22 | 0.17 | 0.07 | 0.08 | 0.09 | 0.12 | 0.12 |
Share Based Compensation of Revenue |
58.42% | 28.99% | 20.73% | 6.59% | 11.81% | 6.62% | 18.71% | 14.63% | 16.81% | 12.06% |
Graham Net Nets |
(0.29) | (0.41) | (0.91) | (0.56) | (0.58) | (0.12) | (0.38) | (1.22) | (8.28) | (3.98) |
Graham Number |
77.10 | 91.97 | 143.89 | 110.39 | 108.66 | 0.00 | 37.22 | 51.47 | 58.56 | 9.17 |
Earnings Yield |
(36.01%) | (35.12%) | (62.51%) | (19.78%) | (34.29%) | (4.43%) | (33.54%) | (88.75%) | (389.78%) | (12.74%) |
Free Cash Flow Yield |
(26.02%) | (28.44%) | (52.06%) | (4.33%) | (26.48%) | (2.49%) | (31.11%) | (80.61%) | (270.02%) | (82.30%) |
Revenue per Share |
5.19 | 8.71 | 6.64 | 22.23 | 10.22 | 25.83 | 6.96 | 8.74 | 4.82 | 3.84 |
Operating CF per Share |
(18.37) | (19.15) | (23.67) | (2.77) | (16.13) | 0.89 | (12.45) | (12.53) | (7.37) | (2.60) |
Capex per Share |
(2.88) | (0.61) | (0.65) | (0.69) | (0.40) | (2.46) | (2.21) | (0.37) | (0.03) | 0.01 |
Free Cash Flow per Share |
(21.24) | (19.76) | (24.32) | (3.46) | (16.53) | (1.57) | (14.65) | (12.90) | (7.40) | (2.58) |
Cash per Share |
17.56 | 12.23 | 9.58 | 9.16 | 11.58 | 26.81 | 13.73 | 4.25 | 1.88 | 0.10 |
Shareholders Equity per Share |
(8.99) | (15.41) | (31.51) | (34.28) | (24.52) | 4.19 | (3.90) | (8.29) | (14.27) | (9.34) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(8.99) | (15.41) | (31.51) | (34.28) | (24.52) | 4.19 | (3.90) | (8.29) | (14.27) | (9.34) |
Free Cash Flow |
(92.48) | (97.23) | (134.69) | (23.34) | (142.56) | (18.01) | (206.44) | (230.79) | (158.87) | (76.84) |
Working Capital |
50.46 | 17.12 | 6.75 | (35.67) | (16.10) | 175.03 | 24.17 | (143.48) | (175.83) | (190.05) |
Capital Expenditures |
(12.52) | (3.00) | (3.59) | (4.66) | (3.47) | (28.16) | (31.06) | (6.59) | (0.55) | 0.35 |
Net Current Asset Value |
(104.80) | (140.66) | (236.14) | (300.14) | (312.23) | (86.07) | (255.34) | (349.88) | (487.12) | (371.22) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.70 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.55 | 0.07 | 0.10 | 0.03 | 0.04 | 0.10 | 0.32 | 0.04 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.23 | 0.25 | 0.25 | 0.27 | 0.11 | 0.05 | 0.10 | 0.11 | 0.65 |
Cash ROIC |
(55.05%) | (65.96%) | 124.56% | 15.01% | 155.10% | (4.89%) | (136.16%) | 388.82% | 68.24% | 33.38% |
Accounts Receivable Turnover |
2.13 | 6.87 | 35.50 | 17.42 | 10.11 | 221.06 | 46.03 | 10.94 | 7.89 | 30.79 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.15 | 0.15 | 0.30 | 0.06 | 0.01 | 0.01 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 2,643.88 | 3,206.74 | 1,413.96 | 7,209.19 | 46,165.74 | 29,638.21 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
10.58 | 6.24 | 1.04 | 8.62 | 8.73 | 1.34 | 2.13 | 14.29 | 13.12 | 3.71 |
Average Payables |
4.96 | 6.76 | 10.86 | 13.59 | 15.29 | 23.75 | 35.71 | 51.19 | 61.46 | 72.23 |
Average Inventory |
0.09 | 0.08 | 0.07 | — | — | — | — | — | — | — |
Average Assets |
199.61 | 147.69 | 137.40 | 145.87 | 184.92 | 340.24 | 439.76 | 363.73 | 270.09 | 226.53 |
Average Common Equity |
15.80 | (57.47) | (125.18) | (202.94) | (221.42) | (81.79) | (3.50) | (101.64) | (227.40) | (292.14) |
Columns are period end dates